About this Research Topic
Myc is a pleiotropic transcription factor fundamental for many cellular processes. It is an infamous and highly-studied oncogene, with around 10,000 articles published in the last decade. The majority of these link it to cancer. The focus on Myc as a hot target in cancer has led to immense efforts – from academia through to pharmaceutical companies – being directed towards finding a Myc inhibitor. Not surprisingly, given its fundamental nature in many physiological processes, Myc has also been linked to a large variety of pathologies other than cancer. The growing efforts to develop Myc inhibitors as cancer therapies will have important implications for the treatment of these diseases too, whether they have a clearly-demonstrated aetiology linked with Myc, or so far are only at early stages of association with it. Interestingly, the activation of Myc may also prove helpful in the field of regenerative medicine and reversal of ageing.
The aim of this Research Topic is therefore to describe non-oncological pathologies and conditions to which Myc modulation could be applied. These will include conditions that have strong links to Myc and where Myc modulation has already been modelled, as well as conditions that so far have more limited data linking them to Myc but where it seems to have a key role. Authors will be expected to briefly review the particular disease and what is known to link Myc to it, plus the possibility of any clinical trials in the near future.
The scope of this Research Topic includes any disease or medical condition outside of oncology in which Myc may play a role and therefore to which Myc modulation could be applied in the clinic.
We are particularly interested in Review, Perspective, Opinion and Original Research Articles, although relevant manuscripts of all types will be considered. We welcome manuscripts focusing on, but not limited to, the following themes:
· Myc inhibition in the context of pathologies such as tuberculosis, multiple sclerosis, hepatitis,
and polycystic kidney disease.
· Myc inhibition in the context of conditions such as endometriosis, asthma, and
osteoarthritis.
· Myc inhibition in non-oncological hyperproliferative disorders.
· Myc inhibition in the context of ageing.
· Myc activation in the context of regeneration and stem cell medicine.
· Approaches to inhibit Myc.
The aim of this Research Topic is therefore to describe non-oncological pathologies and conditions to which Myc modulation could be applied. These will include conditions that have strong links to Myc and where Myc modulation has already been modelled, as well as conditions that so far have more limited data linking them to Myc but where it seems to have a key role. Authors will be expected to briefly review the particular disease and what is known to link Myc to it, plus the possibility of any clinical trials in the near future.
The scope of this Research Topic includes any disease or medical condition outside of oncology in which Myc may play a role and therefore to which Myc modulation could be applied in the clinic.
We are particularly interested in Review, Perspective, Opinion and Original Research Articles, although relevant manuscripts of all types will be considered. We welcome manuscripts focusing on, but not limited to, the following themes:
· Myc inhibition in the context of pathologies such as tuberculosis, multiple sclerosis, hepatitis,
and polycystic kidney disease.
· Myc inhibition in the context of conditions such as endometriosis, asthma, and
osteoarthritis.
· Myc inhibition in non-oncological hyperproliferative disorders.
· Myc inhibition in the context of ageing.
· Myc activation in the context of regeneration and stem cell medicine.
· Approaches to inhibit Myc.
Keywords: myc, therapy, disease target, non-cancerous conditions, non-oncological pathologies, Myc-related pathologies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
